Study details
Enrolling now
Psilocybin or Ketamine for Alcohol Use Disorder
University of Iowa
NCT IDNCT06405607ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
80
Study length
about 2.9 years
Ages
21–65
Locations
1 site in IA
About this study
Researchers are testing whether psilocybin or ketamine can help people with alcohol use disorder. The trial will involve two groups: one group will receive psilocybin, and another group will receive ketamine, both along with therapy.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ketamine
- 2.Take Psilocybin
PhasePhase 2
DrugKetamine
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)
Drug routes
oral
Body systems
Psychiatry / Mental Health